894790-18-2 Usage
Uses
Used in Pharmaceutical Research:
Methyl 2-(Cbz-aMino)-2-(tetrahydrothiopyran-4-ylidene)acetate is utilized as a key intermediate in the development of new medications, particularly for its role in the synthesis of complex organic molecules and potential therapeutic agents. Its unique structure allows for the exploration of novel drug candidates with improved efficacy and selectivity.
Used in Organic Synthesis:
In the field of organic synthesis, Methyl 2-(Cbz-aMino)-2-(tetrahydrothiopyran-4-ylidene)acetate serves as a versatile building block for the creation of a wide range of organic compounds. Its functional groups and heterocyclic components enable the formation of diverse chemical entities, expanding the scope of synthetic chemistry.
Used in Amino Acid Derivative Studies:
As a derivative of the amino acid alanine, Methyl 2-(Cbz-aMino)-2-(tetrahydrothiopyran-4-ylidene)acetate is employed in the study of amino acid derivatives, providing insights into the structure-activity relationships and potential applications of these bioactive molecules in various biological processes.
Used in Heterocyclic Compound Research:
The presence of the tetrahydrothiopyran ring in Methyl 2-(Cbz-aMino)-2-(tetrahydrothiopyran-4-ylidene)acetate makes it an attractive candidate for research on heterocyclic compounds. Its unique structure allows for the investigation of the properties and potential applications of heterocyclic systems in medicinal chemistry and other related fields.
Check Digit Verification of cas no
The CAS Registry Mumber 894790-18-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,9,4,7,9 and 0 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 894790-18:
(8*8)+(7*9)+(6*4)+(5*7)+(4*9)+(3*0)+(2*1)+(1*8)=232
232 % 10 = 2
So 894790-18-2 is a valid CAS Registry Number.
894790-18-2Relevant academic research and scientific papers
FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
-
Paragraph 1156, (2017/05/14)
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF
-
Paragraph 0848, (2015/08/03)
The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.
Heterocyclic side chain containing metalloprotease inhibitors
-
, (2008/06/13)
The compounds have a structure according to the following Formula (I): are effective in treating conditions characterized by excess activity of metalloprotease enzymes.
